Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
HROW Transcript
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights strong growth in TRIESENCE and IHEEZO, with substantial unit demand increases. While revenue challenges exist due to inventory and pricing adjustments, optimistic guidance for future quarters and strategic product launches (BYQLOVI, BYOOVIZ) indicate potential growth. The Q&A section reveals analysts' positive sentiment towards sales force expansion and product demand. Despite some uncertainties, such as VEVYE's pricing issue, the overall outlook is positive due to strong product performance, strategic expansion, and expected revenue normalization, supporting a positive stock price movement prediction.
Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call highlighted strong product development and market strategy, with plans to launch new products and expand market reach. Despite a slight revenue guidance downgrade, optimistic future projections for products like VEVYE and TRIESENCE, and positive Q&A insights, bolster sentiment. The company's focus on expanding its sales force and improving product pricing further supports a positive outlook. The lack of specific guidance for some products was noted, but overall, the strategic initiatives and optimistic projections suggest a positive stock movement.
Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript
Positive11-11
The earnings call summary and Q&A highlight strong product development and market strategy, especially with VEVYE's market penetration and new PBM coverage. Although there are concerns regarding ASP decline and inventory shortages, the overall sentiment is positive due to expected revenue growth, strategic expansions, and leverage on SG&A. The positive guidance and strategic market moves outweigh the potential risks, leading to a likely positive stock price movement.
Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call summary indicates strong growth in key revenue segments like IHEEZO and TRIESENCE, with positive guidance for the future. Despite a decline in VEVYE revenue, prescription volumes are up, and ASPs are expected to rise. The Q&A section reveals management's confidence in growth strategies and upcoming launches, although some uncertainty remains around biosimilar timing. Overall, the positive growth outlook and strategic initiatives suggest a likely positive stock price movement.
HROW Slides
HROW Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
